Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.61 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.61 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.61 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.61 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.61 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527497 | 0.90 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4509427 | 0.90 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4520373 | 0.90 | GRIN2D (0.76) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4512606 | 0.83 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4521303 | 0.77 | GRIN2D (0.74) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4514981 | 0.77 | GRIN2D (0.73) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7158932 | 0.76 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4143776 | 0.75 | CYP2C9 (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4519952 | 0.74 | GRIN2D (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4805201 | 0.74 | GRIN2D (0.80) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012118-A1 | Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-01-08 | — | — | US | claimed |
| EP-1771436-A1 | KYNURENIC ACID AMIDE DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | Richter Gedeon Vegy Szeti Gy R Rt. (HU) | 2007-04-11 | — | — | EP | claimed |
| WO-2006010967-A1 | KYNURENIC ACID AMIDE DERIVATIVES AS NR2B RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2006-02-02 | — | — | WO | claimed |
| US-20090012118-A1 | Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012118-A1 | Kynurenic Acid Amide Derivatives as Nr2b Receptor Antagoni | GRIN1, GRIN2A, GRIN2B | GRIN2D 5/4885GRIN3B 8/4885GRIN1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.